We chat with Tesla La Touche who is the Founder and CEO of Aphrodite Health, the first ever female-founded biotech company within the medicinal psychedelic industry.
Similar Posts
Cathie Wood of Ark Invest Comments on Psychedelic Stocks like MindMed “We DON’T Invest In Binaries”
Will Ark Invest (ARKK) and Cathie Wood invest in MindMed ( MMED / MMEDF/ MMQ) or other Psychedelic Stocks? In this episode, Cathie Wood talks to Kevin O’Leary about the potential for psychedelic stocks and MindMed.
Kevin O’Leary is a BIG bull in MindMed, but what does Cathie Wood think? Will Ark invest in MindMed? Well, no. She is clear that Ark does not invest in binary outcomes, which MMED / MMEDF cleary is.
Having said this, the door may be left open for the future, as ARKK invests in Healthcare companies using artifical intellegence, exactly what MindMed’s Albert division is working on. Also, once clinical trial results come in, MindMed will no longer be a binary choice. SO anything is possible.
I hope this little impromptu episode added some life and joy to your live and that you guys found some value in this.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedNews #PsychedelicStocks
Consolidating Plant Medicine, Permaculture and Indigenous Wisdom With Colette Condorcita, Decriminalize Philadelphia
In this episode, Colette describes her diverse background working closely with plant medicines and Indigenous groups in South America, how psychedelics are intrinsically aligned with permaculture and the cultivation of sacred plants, and much more.
HAVN Life Sciences Update
HAVN Life Sciences Inc. CEO, Tim Moore, updates the recent…
Functional Fungi and Microdosing for Optimal Wellbeing with Alli Schaper, Into The Multiverse
In this episode, Alli speaks on functional mushrooms for health: what they are, why they’re important, and what benefits they provide. She also delves into how functional mushrooms, when combined with psychoactive mushrooms such as psilocybin, impact the body.
Spotlight Roundup-Another Psychedelic Company Lists On The Nasdaq
June 9, 2021- This week’s Psychedelic Business News top stories…
MindMed Stock Catalysts for 2021: NASDAQ, Clinical Trial Results and More (MMED / MMEDF)
In today’s episode, we discuss :MindMed Stock Catalysts for 2021: NASDAQ, Clinical Trial Results and More (MMED / MMEDF).
2020 was a wild year for MindMed, with the company IPOing in March, at just over 20c/ share, all prices in American currency. Then, the MindMed stock price shot up to a high of $4.37 in December, only to fall about 30% and consolidate around $3 a share in the new year.
But what will be the main catalysts for MindMed and its stock going forward in 2021? Put another way, what are the events and dates that shareholders and potential investors should circle on their calendars?
In this episode, we are going to talk about several catalysts to look out for
1. MindMed’s Nasdaq uplisting
– When to expect MindMed to join the Nasdaq?
– Is MindMed’s uplisting a sure thing?
-What will happen to MindMed stock if/when the company gets uplisted?
2. Clinical trials wrapping up, and data being released by MindMed
– Important dates MindMed investors should circle in their calendars
3. MindMed’s quarter end financial reporting
4. MindMed conference calls
Unknown Catalysts for Mindmed:
1. Clinical trials expansions
2. Financial agreements
** Also, on the 20th of January, Kevin O’Leary and Jr Rahn went live discussing MindMed. For those who haven’t seen it, Jr mentioned a few extra catalysts we should be looking forward to which we will discuss in our next episode.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://www.prnewswire.com/news-releases/atai-life-sciences-announces-closing-of-125-million-series-c-financing-round-301178915.html
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MMEDF